Orexo receives million 5£ milestone payment for Abstral®

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Dec 17, 2014 at 3:00 AM

Orexo receives million 5£ milestone payment for Abstral® in Europe and Zubsolv® continues strong market share growth in the US

Uppsala, Sweden – December 17, 2014 – The annual sales of Abstral in Europe has passed million 60€ during 2014, which triggers a milestone payment of million 5£ (approx. million 60 SEK) to Orexo AB (”Orexo”) from the commercial partner in Europe ProStrakan Group plc (”ProStrakan”). According to the agreement from June 2012, with ProStrakan for Abstral sales in Europe, Orexo receive a fixed and non-conditional royalty of million 55£, a variable royalty for annual sales exceeding million 42.5€ and milestone payments of up to million 10£. The threshold for the variable royalty was reached during Q3 and Orexo will receive royalty for all sales of Abstral in Europe in Q4. The fixed and non-conditional Abstral royalties will reach million 174 SEK for the full year. These fixed royalties represents an amortization of the final fixed and unconditional payment related to the agreement with ProStrakan. The fixed payment will be fully recognized in the P&L by May 2015 and will have no cash impact, as the payments have all been received. ”I am pleased to follow the continued success of our commercial partner ProStrakan with Abstral in Europe. The continued development of Abstral in Europe is a strong evidence of the patient and physician preference of the attributes of Orexo’s sublingual products. The development of Abstral enables Orexo to further invest in the commercialization and development of Zubsolv, accelerating the positive momentum for the product and the overall market for opioid dependence treatment.” said Nikolaj Sørensen, CEO and President of Orexo AB. The demand and market share of Zubsolv continue a positive development. The last four weeks Zubsolv has reached 5.6% of the market (daily dosages) compared to 4.2% the last month of Q3. The growth in Q4 can be equally explained by the exclusive agreement with the Managed Medicaid provider WellCare and growth from increased demand from patient with private health insurance and patients paying out-of-pocket. Exclusive agreements are associated with higher rebates and have a negative short term impact on the gross to net revenue ratio, but have proven to drive growth in the more profitable non-exclusive business segments. For further information, please contact: Nikolaj Sørensen, President and CEO Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com Henrik Juuel, CFO and EVP Tel: +46 (0)722-20 94 77, E-mail: ir@orexo.com About Orexo AB Orexo is a specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery. The company is commercializing its proprietary product, ZUBSOLV® sublingual tablets, for maintenance treatment of opioid dependence, in the United States. The ZUBSOLV sublingual tablet is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the US, EU and Japan. Orexo AB, with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange (STO: ORX) and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and HealthCap. For information about Orexo and Zubsolv, please visit www.orexo.com and www.zubsolv.com. About Abstral Abstral is the leading fast-acting fentanyl product in EU intended for treatment of breakthrough pain in cancer patients. Abstral employs Orexo’s proprietary sublingual delivery technology (under the tongue). After the product development Abstral was out-licensed to Kyowa Hakko Kirin Co., Ltd and the European subsidiary ProStrakan Group plc, which still holds the rights in the EU and Japan, whereas Galena Biopharma Inc holds the rights for Abstral in the US. For information about Abstral, please visit www.abstral.com. Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 8:45am CET on December 17, 2014.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TBL Carves New Path with New York License Win

Punching Through to New Opportunities Folks, here's one for the record books: the Team Boxing League (TBL) just nabbed the promoter license from the New York State Athletic Commission, or NYSAC if you're into the alphabet soup. This isn't just paperwork getting shuffled around an office; it's a massive leap forward for team boxing, a sport that steps into the heart of New...

mF International Shuts Down Legacy Business to Focus on BCH

mF International's Bold Digital Leap It’s a big move in the financial landscape when a firm decides to shake things up and pivot hard towards the digital frontier. mF International Limited (NASDAQ:MFI) is shutting the door on its legacy financial trading solutions and dedicating itself entirely to the budding world of digital assets. This isn’t just another facelift;...

Space Cybersecurity: $8.59B Market Opportunity by 2031

Unraveling the Cybersecurity Frontier in Space These days, keeping our tech safe isn't just about stopping your phone from getting hacked or your laptop from being bombarded with spam. We're talking bigger, and I mean cosmos-level bigger. The space cybersecurity scene is ramping up, projected to balloon from $5.52 billion in 2026 to a whopping $8.59 billion by 2031....

Beta Bionics Faces Class Action Lawsuit Amid FDA Concerns

Beta Bionics in the Legal Crosshairs When a company like Beta Bionics gets hauled into court, you know it's not just smoky mirrors and boardroom politics. The stakes are high right now, with investors lining up for a class-action lawsuit that zeroes in on a nasty bundle of allegations. This isn't just a blip on the radar. It's a seismic wave in the industry. Allegations...

LifeSecure Expands with Starscape Agency Launch

LifeSecure's Strategic Move into the Insurance Space LifeSecure Holdings Corporation is planting new roots with its latest venture, Starscape Insurance Agency. This ain't just another splash in the kiddie pool, buddy. This is a big step in bolstering its standing in the insurance sector, focusing sharply on health insurance solutions for individuals, families, and even...

Americas Cardroom Smashes Prize Pools; Bahamas Up Next

Ah, poker. Where dreams are won with a flick of the wrist and a well-placed bluff. This week, it was all eyes on Americas Cardroom’s Dual Venom PKOs, and let me tell you, they didn't just meet expectations—they chewed them up and spat them out like yesterday's jam. Two Titans Crowned in Poker Showdown The action wrapped up with a jaw-dropping $6,862,500 prize pool....

Malteurop's Big Bet in China: A Malt Monopoly Move

Malteurop’s Ambitious Leap into China Folks, it looks like Malteurop, the malting arm of the French VIVESCIA Group, is digging its French roots deep into Chinese soil with a move that screams strategy. They’ve just scooped up the Chunlei Malting Co. plant in Jiangsu province, which cranks out enough malt to sling two billion liters of beer annually. Yeah, that's quite...

Amazon OIL9 Drivers Join Teamsters, Demand Better Pay

Amazon's OIL9 Facility Faces Union Uprising Never a dull moment with Amazon, is there? Just when you think you've seen it all in the labor struggle world, drivers at Amazon's OIL9 facility in Merrillville, Indiana, decide to join the Teamsters. These folks are not just making deliveries; they're laying down the battle lines, demanding Amazon acknowledge their union and...

Energy Services Expands with FAMCO Acquisition

Digging Deeper into Energy Services' Next Move Alright, listen up. Today we're diving into Energy Services of America's latest play. They just wrapped up a juicy acquisition, snagging up FAMCO, a utility contractor from West Virginia, for a cool $6.95 million. It's a mix of cold hard cash and some stock from Energy Services' own treasure chest, with a bit put on hold...

Cowfest 2026 Delighted by Frederick's Flying Cows

Moo-ving Towards a New Record Alright, listen up. This fall, there's a bovine spectacle coming to Maryland that's more than just a trip down to the fairgrounds—it's Cowfest 2026, baby! Now, if you're scratching your head thinking this is just another seasonal shindig, you're underestimating what's mooing across Frederick County. The Flying Cows are ready to take the...